Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | PSMD14 | O00487 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 6/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.80 |
| ▸ | HTR7 | P34969 | 7/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.54 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 9/20 | 0.51 |
| ▸ | HTR2A | P28223 | 8/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22800099 | 1.00 | MAPT (1.00) | MAPTKDM4EPOLBGAAPSMD14 | |
| Hydrochloric Acid SCHEMBL31289351 | 0.99 | MAPT (0.97) | MAPTKDM4EPOLBGAAPSMD14 | |
| Hydrochloric Acid SCHEMBL31289353 | 0.99 | MAPT (0.97) | MAPTKDM4EPOLBGAAPSMD14 | |
| SCHEMBL31289358 | 0.97 | MAPT (0.95) | MAPTKDM4EPOLBGAAPSMD14 | |
| Adrenoglomerulotropin SCHEMBL356345 | 0.89 | HTR2B (1.00) | MAPTKDM4EPOLBGAAPSMD14 | |
| SCHEMBL763727 | 0.82 | HTR7 (0.72) | MAPTKDM4EPOLBGAAPSMD14 | |
| SCHEMBL15236165 | 0.81 | MAPT (0.68) | MAPTKDM4EPOLBGAAPSMD14 | |
| SCHEMBL6239907 | 0.81 | MAPKAPK2 (0.82) | MAPTKDM4EPOLBGAAPSMD14 | |
| SCHEMBL8321957 | 0.80 | MAPT (0.67) | MAPTKDM4EPOLBGAAPSMD14 | |
| SCHEMBL12067592 | 0.80 | HTR2B (0.67) | MAPTKDM4EPOLBGAAPSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 483 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137652-A1 | Composition Comprising Non-Phosphorylated Tryptamine | SINTALICA S R L (IT) | 2026-05-21 | — | — | US | claimed |
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | Natural MedTech Pty Ltd (AU) | 2025-11-06 | — | — | US | claimed |
| EP-4638419-A1 | NON-HALLUCINOGENIC TRYPTAMINE COMPOUNDS, PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Sintalica S.r.l. (IT) | 2025-10-29 | — | — | EP | claimed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4615444-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural Medtech Pty Ltd (AU) | 2025-09-17 | — | — | EP | claimed |
| US-20250281399-A1 | A MUCOADHESIVE FILM COMPRISING A PHARMACEUTICALLY ACTIVE AGENT AND USES THEREOF | SHORT WAVE PHARMA INC. (CA) | 2025-09-11 | — | — | US | claimed |
| EP-4601655-A1 | DELIVERY SYSTEM FOR THE CONTROLLED RELEASE OF PSYCHEDELIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Sintalica S.r.l. (IT) | 2025-08-20 | — | — | EP | claimed |
| EP-4601665-A1 | COMPOSITION COMPRISING TRYPTAMINES AND MAOIS COMPOUNDS SELECTED FROM ?-CARBOLINE INHIBITORS, AND PHARMACEUTICAL USES THEREOF | Sintalica S.r.l. (IT) | 2025-08-20 | — | — | EP | claimed |
| EP-4601627-A1 | COMPOSITION COMPRISING NOT PHOSPHORYLATED TRYPTAMINE, ANTIOXIDANTS, AND SUPPLEMENTS, AND PHARMACEUTICAL USES THEREOF | Sintalica S.r.l. (IT) | 2025-08-20 | — | — | EP | claimed |
| EP-4518855-A1 | A MUCOADHESIVE FILM COMPRISING A PHARMACEUTICALLY ACTIVE AGENT AND USES THEREOF | Short Wave Pharma Inc. (CA) | 2025-03-12 | — | — | EP | claimed |
| CN-102791134-A | Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions | PERKINELMER INC | 2012-11-21 | — | — | CN | claimed |
| EP-2506717-A1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | PerkinElmer, Inc. (US) | 2012-10-10 | — | — | EP | claimed |
| WO-2011069051-A1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | CALIPER LIFE SCIENCES, INC. (US) | 2011-06-09 | — | — | WO | claimed |
| US-20090104196-A1 | Antibodies For Use in Identifying and/or Scoring Prostate Cancer and Androgen Receptor-Dependent Gene Expression Control | UNIVERSITAETSKLINIKUM FREIBURG (DE) | 2009-04-23 | — | — | US | claimed |
| US-20080139665-A1 | Androgen Receptor-Dependent Gene Expression Control | UNIVERSITAETSKLINIKUM FREIBURG (DE) | 2008-06-12 | — | — | US | claimed |
| WO-2007006581-A2 | TARGETING LSD1 FOR USE IN IDENTIFYING AND/OR SCORING PROSTATE CANCER AND FOR CONTROLLING ANROGEN RECEPTOR-DEPENDENT GENE EXPRESSION | Universitätsklinikum Freiburg (DE) | 2007-01-18 | — | — | WO | claimed |
| EP-1704859-A1 | Androgen receptor-dependent gene expression control by inhibiting the amine oxidase activity of lysine-specific demethylase (LSD1) | Universitätsklinikum Freiburg (DE) | 2006-09-27 | — | — | EP | claimed |
| WO-2006087206-A2 | ANDROGEN RECEPTOR-DEPENDENT GENE EXPRESSION CONTROL BY INHIBITING THE AMINE OXIDASE ACTIVITY OF LYSINE-SPECIFIC DEMETHYLASE (LSD1) | Universitätsklinikum Freiburg (DE) | 2006-08-24 | — | — | WO | claimed |
| EP-1693062-A2 | Androgen receptor-dependent gene expression control | Universitätsklinikum Freiburg (DE) | 2006-08-23 | — | — | EP | claimed |
| US-5591738-A | Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof | NDA INTERNATIONAL, INC. (US) | 1997-01-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281399-A1 | A MUCOADHESIVE FILM COMPRISING A PHARMACEUTICALLY ACTIVE AGENT AND USES THEREOF | MUC1, CFTR, LIPA | MAPT 1012/4885KDM4E 4859/4885POLB 2204/4885 |
| US-20260137652-A1 | Composition Comprising Non-Phosphorylated Tryptamine | HTR2B, BDNF, HTR3B | MAPT 705/4885KDM4E 4470/4885POLB 1077/4885 |
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | MAOA, MAOB, TPH1 | MAPT 801/4885KDM4E 1199/4885POLB 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.